| Primary |
| Pneumonia |
24.1% |
| Drug Use For Unknown Indication |
18.2% |
| Pneumonia Aspiration |
7.1% |
| Hypertension |
5.8% |
| Product Used For Unknown Indication |
4.5% |
| Sepsis |
4.3% |
| Cystic Fibrosis |
3.5% |
| Diabetes Mellitus |
3.4% |
| Infection |
3.2% |
| Pyrexia |
3.2% |
| Urinary Tract Infection |
2.7% |
| Prophylaxis |
2.5% |
| Constipation |
2.4% |
| Insomnia |
2.4% |
| Osteomyelitis |
2.4% |
| Pyelonephritis |
2.4% |
| Epilepsy |
2.3% |
| Cellulitis |
2.0% |
| Febrile Neutropenia |
1.9% |
| Pneumonia Bacterial |
1.8% |
|
| Thrombocytopenia |
11.7% |
| Renal Failure Acute |
9.8% |
| Rash |
7.3% |
| Hepatic Function Abnormal |
6.5% |
| Interstitial Lung Disease |
6.5% |
| Tubulointerstitial Nephritis |
6.3% |
| Liver Disorder |
5.4% |
| Pancytopenia |
4.6% |
| Pyrexia |
4.6% |
| Toxic Epidermal Necrolysis |
4.3% |
| Platelet Count Decreased |
4.1% |
| Respiratory Failure |
4.1% |
| White Blood Cell Count Decreased |
4.1% |
| Renal Impairment |
3.3% |
| Neutropenia |
3.0% |
| Renal Disorder |
3.0% |
| Renal Failure |
3.0% |
| Vomiting |
3.0% |
| Anaphylactic Reaction |
2.7% |
| Hepatic Failure |
2.7% |
|
| Secondary |
| Product Used For Unknown Indication |
19.3% |
| Drug Use For Unknown Indication |
17.5% |
| Pneumonia |
11.3% |
| Acute Lymphocytic Leukaemia |
5.6% |
| Hypertension |
5.2% |
| Pyrexia |
4.1% |
| Prophylaxis |
4.0% |
| Interstitial Lung Disease |
3.3% |
| Diabetes Mellitus |
3.2% |
| Febrile Neutropenia |
2.9% |
| Constipation |
2.5% |
| Gastrointestinal Infection |
2.5% |
| Neuropathy Peripheral |
2.5% |
| Sepsis |
2.5% |
| Osteomyelitis |
2.4% |
| Pneumonia Aspiration |
2.3% |
| Disseminated Intravascular Coagulation |
2.2% |
| Infection |
2.2% |
| Infection Prophylaxis |
2.2% |
| Nasopharyngeal Cancer |
2.2% |
|
| Interstitial Lung Disease |
9.5% |
| Toxic Epidermal Necrolysis |
8.6% |
| Renal Failure Acute |
7.6% |
| Renal Impairment |
6.2% |
| Nephropathy Toxic |
5.7% |
| Pyrexia |
5.7% |
| Thrombocytopenia |
5.7% |
| Tubulointerstitial Nephritis |
5.7% |
| Hepatic Function Abnormal |
4.8% |
| Vomiting |
4.8% |
| Drug Hypersensitivity |
4.3% |
| Lymphopenia |
4.3% |
| Sepsis |
3.8% |
| White Blood Cell Count Decreased |
3.8% |
| Hyperbilirubinaemia |
3.3% |
| Pneumonia Aspiration |
3.3% |
| Renal Failure |
3.3% |
| Residual Urine |
3.3% |
| Respiratory Failure |
3.3% |
| Ovarian Cancer |
2.9% |
|
| Concomitant |
| Product Used For Unknown Indication |
44.0% |
| Drug Use For Unknown Indication |
22.1% |
| Prophylaxis |
7.1% |
| Pain |
3.3% |
| Infection Prophylaxis |
2.9% |
| Pneumonia |
2.7% |
| Hypertension |
2.3% |
| Multiple Myeloma |
1.8% |
| Crohn's Disease |
1.6% |
| Acute Myeloid Leukaemia |
1.6% |
| Sepsis |
1.5% |
| Nausea |
1.5% |
| Infection |
1.2% |
| Constipation |
1.1% |
| Anxiety |
1.0% |
| Febrile Neutropenia |
0.9% |
| Diabetes Mellitus |
0.9% |
| Myelodysplastic Syndrome |
0.9% |
| Aplastic Anaemia |
0.9% |
| Depression |
0.8% |
|
| Vomiting |
12.8% |
| Sepsis |
10.4% |
| White Blood Cell Count Decreased |
10.1% |
| Pneumonia |
8.4% |
| Renal Failure Acute |
6.6% |
| Weight Decreased |
5.4% |
| Thrombocytopenia |
4.8% |
| Respiratory Failure |
4.5% |
| Urinary Tract Infection |
3.9% |
| Unresponsive To Stimuli |
3.6% |
| White Blood Cell Count Increased |
3.5% |
| Death |
3.4% |
| Febrile Neutropenia |
3.4% |
| Renal Failure |
3.4% |
| Platelet Count Decreased |
2.8% |
| Pyrexia |
2.8% |
| Interstitial Lung Disease |
2.7% |
| Pulmonary Embolism |
2.6% |
| Weight Increased |
2.5% |
| Injury |
2.3% |
|
| Interacting |
| Product Used For Unknown Indication |
77.2% |
| Fungal Infection |
7.0% |
| Haemoptysis |
3.5% |
| Pneumonia |
3.5% |
| Respiratory Failure |
3.5% |
| Tachycardia |
3.5% |
| Analgesic Therapy |
1.8% |
|
| Drug Interaction |
25.0% |
| Hepatic Function Abnormal |
25.0% |
| Vision Blurred |
25.0% |
| Agranulocytosis |
12.5% |
| Interstitial Lung Disease |
12.5% |
|
